Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • European Lung Cancer Congress - ELCC

European Lung Cancer Congress - ELCC

March 25 - 28, 2026

  1. All
  2. Durvalumab
  3. Osimertinib
  4. Volrustomig
  5. Savolitinib
  6. Dato-DXd
  7. T-DXd

PDF

Bifidobacterium longum (B. longum) abundance is associated with treatment (Tx) response to immunotherapy (IO) in patients (pts) with resectable NSCLC (R-NSCLC): exploratory analyses from AEGEAN

PDF

Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase 3 ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

PDF

Primary lung tumour laterality, molecular characteristics, and prognostic impact in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC) in the phase 3 CASPIAN trial

PDF

Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY

PDF

DeLLphi-312 phase 3 trial-in-progress: tarlatamab with durvalumab, carboplatin and etoposide versus durvalumab, carboplatin and etoposide as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC)

PPT

NeoADAURA: Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) outcomes following neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CTx) vs placebo (PBO) + CTx in patients (pts) with (w) resectable, EGFRm Stage II–IIIB NSCLC

PDF

Chemotherapy (chemo) rechallenge in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC who discontinued 1L osimertinib (osi) + platinum-pemetrexed (plat-pem) due to progression (PD): FLAURA2 exploratory analysis

PPT

Osimertinib with or without chemotherapy in EGFR-mutated advanced non-small cell lung cancer (NSCLC) with concurrent TP53 mutations

PDF

Estimated Time Toxicity Associated with Utilization of First Line Treatment for EGFR Mutated Non-Small Cell Lung Cancer in the European Union

PDF

Results from a Global Physician Based Survey on Factors Guiding Treatment Decision making in a Changing First Line EGFRm Advanced NSCLC Landscape

PDF

Volrustomig, a novel bispecific PD-1/CTLA-4 monoclonal antibody, as single-agent first-line (1L) therapy for unresectable pleural mesothelioma (PM): substudy 5 of the eVOLVE-02 phase 2 study

PDF

A Global Physician Based Survey on Testing and Treatment following MET-Driven Progression on EGFR TKIs in Advanced NSCLC

PDF

Identification of DXd sensitivity biomarkers and osimertinib induced datopotamab deruxtecan (Dato-DXd) internalization as potential mechanisms for enhanced activity of Dato-DXd in preclinical models of EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC)

PDF

TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) ± osimertinib (osi) in EGFR-mutated (EGFRm) NSCLC

PDF

TROPION-Lung17: A randomised phase 3 study of datopotamab deruxtecan (Dato-DXd) vs docetaxel in patients with previously-treated TROP2-NMR positive advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA)

PDF

Full device assessment of TROP2 Normalized Membrane Ratio in Non-Small Cell Lung Carcinoma using a computational pathology algorithm in Real-world laboratories

PDF

Trastuzumab Deruxtecan - Planchard D et al. DESTINY-Lung03 Part 5 ELCC 2026 (TiP)

PDF

Bifidobacterium longum (B. longum) abundance is associated with treatment (Tx) response to immunotherapy (IO) in patients (pts) with resectable NSCLC (R-NSCLC): exploratory analyses from AEGEAN

PDF

Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase 3 ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

PDF

Primary lung tumour laterality, molecular characteristics, and prognostic impact in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC) in the phase 3 CASPIAN trial

PDF

Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY

PDF

DeLLphi-312 phase 3 trial-in-progress: tarlatamab with durvalumab, carboplatin and etoposide versus durvalumab, carboplatin and etoposide as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC)

PPT

NeoADAURA: Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) outcomes following neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CTx) vs placebo (PBO) + CTx in patients (pts) with (w) resectable, EGFRm Stage II–IIIB NSCLC

PDF

Chemotherapy (chemo) rechallenge in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC who discontinued 1L osimertinib (osi) + platinum-pemetrexed (plat-pem) due to progression (PD): FLAURA2 exploratory analysis

PPT

Osimertinib with or without chemotherapy in EGFR-mutated advanced non-small cell lung cancer (NSCLC) with concurrent TP53 mutations

PDF

Estimated Time Toxicity Associated with Utilization of First Line Treatment for EGFR Mutated Non-Small Cell Lung Cancer in the European Union

PDF

Results from a Global Physician Based Survey on Factors Guiding Treatment Decision making in a Changing First Line EGFRm Advanced NSCLC Landscape

PDF

Volrustomig, a novel bispecific PD-1/CTLA-4 monoclonal antibody, as single-agent first-line (1L) therapy for unresectable pleural mesothelioma (PM): substudy 5 of the eVOLVE-02 phase 2 study

PDF

A Global Physician Based Survey on Testing and Treatment following MET-Driven Progression on EGFR TKIs in Advanced NSCLC

PDF

Identification of DXd sensitivity biomarkers and osimertinib induced datopotamab deruxtecan (Dato-DXd) internalization as potential mechanisms for enhanced activity of Dato-DXd in preclinical models of EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC)

PDF

TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) ± osimertinib (osi) in EGFR-mutated (EGFRm) NSCLC

PDF

TROPION-Lung17: A randomised phase 3 study of datopotamab deruxtecan (Dato-DXd) vs docetaxel in patients with previously-treated TROP2-NMR positive advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA)

PDF

Full device assessment of TROP2 Normalized Membrane Ratio in Non-Small Cell Lung Carcinoma using a computational pathology algorithm in Real-world laboratories

PDF

Trastuzumab Deruxtecan - Planchard D et al. DESTINY-Lung03 Part 5 ELCC 2026 (TiP)

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States